ClinicalTrials.gg
RecruitingNCT06144554Updated Jul 1, 2026

Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes

An observational study in Type 1 Diabetes, sponsored by Insulet Corporation. Recruiting at 1 site in United States. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2026-07-01.

Sponsored by Insulet Corporation · Observational

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,200
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 14 studies in Diabetes Mellitus, Type 1 by Insulet Corporation — 4 open to participants now, 5 under way, none of them phase 3. Diabetes Mellitus, Type 1 · Insulet Corporation.

Started
2023
with 1 other
Observational
3 of 14
2 open now
Registered
10th of 14
by date

Among the 14 studies in Diabetes Mellitus, Type 1 by Insulet Corporation, this one is one of 2 that started in 2023, is one of 3 observational ones, and was the 10th registered.

Diabetes Mellitus, Type 1

3,756 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

4 of the 14 studies in Diabetes Mellitus, Type 1 by Insulet Corporation are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 416 Diabetes Mellitus, Type 1 studies recruiting now, 129 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 2 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Diabetes Mellitus, Type 1 by Insulet Corporation, or all of them as a file.
02

Study summary

This is a decentralized observational clinical registry to collect real-world evidence related to the safety and effectiveness of the Omnipod 5 system in children and adults with Type 1 Diabetes.

Read the detailed description

This is a decentralized observational clinical registry to collect real-world evidence related to the safety and effectiveness of the Omnipod 5 system in children and adults with Type 1 Diabetes.

A minimum of 2,200 Type 1 participants will be recruited to ensure a minimum of 1,650 participants completing 12 months of follow-up. The minimum number of completed participants is as follows:

  • 150 participants aged 2-5
  • 300 participants aged 6-13
  • 300 participants aged 14-17
  • 900 participants aged 18+

In addition to the enrollment targets above, a minimum of 1100 Omnipod-naïve users, 880 pump-naïve users, and 110 CGM-naïve users will be recruited.

Participants are expected to be followed for 12 months.

03

Conditions studied

  • Type 1 Diabetes

Keywords

  • Type 1 Diabetes
  • Omnipod
  • Automated Insulin Delivery
  • Registry
04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

All new users for the Omnipod 5 System will be required to register with Insulet's Podder Central. Users already in Podder Central will be required to log into their account before logging into the Omnipod 5 Controller if transitioning to the Omnipod 5 System.

A minimum of 2,200 Type 1 participants will be recruited.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Self-reported type 1 diabetes
  2. Prescribed, obtained, and have been using the Omnipod 5 System for no more than two weeks or plan to start using the system within the next two weeks
  3. Willing to use only the following types of U-100 insulin during the study: Humalog U-100, Novolog, or Admelog
  4. Able to read and speak English or Spanish (when available) fluently and reside full time in the United States
  5. Willing to collect samples using a provided home kit and send the samples to the registry specific core laboratory at baseline and 3, 6, 9 and 12 months
  6. Willing and able to complete registry assessments every two weeks
  7. Willing and able to complete registry outcome questionnaires at baseline, 6 months and end of study (or at withdrawal)
  8. Is not currently pregnant or planning to become pregnant in the next 12 months and is using a reliable form of
  9. Access to internet via phone, tablet and/or computer to use the registry online platform
  10. Willing to provide CGM and insulin delivery data collected prior to using the Omnipod 5 System, if available (participants will not be excluded if data is not provided)
  11. Willing and able to provide (or assent) and/or has a parent/guardian willing and able to provide informed consent as applicable

Exclusion criteria

Exclusion Criteria:

  1. Diagnosed with sickle cell anemia and/or hemoglobinopathy
  2. Planned blood transfusions over the course of the study or has received a blood transfusion within 3 months prior to starting on Omnipod 5
  3. Adults that are unable to provide
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Omnipod User

    All new users for the Omnipod 5 System will be required to register with Insulet's Podder Central. Users already in Podder Central will be required to log into their account before logging into the Omnipod 5 Controller if transitioning to the Omnipod 5 System. As part of the onboarding process, users will be invited to participate in this registry.

    Device: Omnipod 5

Interventions

  • DeviceOmnipod 5

    The Omnipod 5 System consists of a tubeless insulin Pod and the Omnipod® 5 App, installed on a designated Controller or compatible Android smartphone. The Omnipod 5 System works with the Dexcom G6® Continuous Glucose Monitoring System to continuously adapt and automatically deliver insulin according to personal needs. Every two weeks while on the Omnipod 5 system, participants will receive a push notification to complete assessments including any severe hypoglycemia or diabetic ketoacidosis events experienced since the prior assessment.

06

What researchers measure

Primary outcomes

  1. Incidence rate of severe hypoglycemia

    Measures frequency of severe hypoglycemia

    Time frame: From baseline to study completion, up to 12 months.

  2. Incidence rate of DKA

    Measures frequency of DKA

    Time frame: From baseline to study completion, up to 12 months.

  3. A1c at 3, 6, 9 and 12 months

    Measures device effectiveness

    Time frame: Comparing the change in A1c at baseline compared to at 3, 6, 9 and 12 months

  4. Percentage of time < 54 mg/dL

    Glucose metric from study continuous glucose monitoring system

    Time frame: From baseline to study completion, up to 12 months

  5. Percentage of time < 70 mg/dL

    Glucose metric from study continuous glucose monitoring system

    Time frame: From baseline to study completion, up to 12 months

  6. Percentage of time > 180 mg/dL

    Glucose metric from study continuous glucose monitoring system

    Time frame: From baseline to study completion, up to 12 months

  7. Percentage of time > 250 mg/dL

    Glucose metric from study continuous glucose monitoring system

    Time frame: From baseline to study completion, up to 12 months

  8. Percentage of time in range 70-180 mg/dL

    Glucose metric from study continuous glucose monitoring system

    Time frame: From baseline to study completion, up to 12 months

  9. Mean Glucose mg/dL

    Glucose metric from study continuous glucose monitoring system

    Time frame: From baseline to study completion, up to 12 months

  10. Standard deviation of glucose mg/dL

    measure of the range of glucose readings

    Time frame: From baseline to study completion, about 12 months

  11. Glucose management indicator %

    MI tells you what your approximate A1C level is likely to be, based on the average glucose level from your CGM readings for 14 or more days.

    Time frame: From baseline to study completion, up to 12 months

  12. Percentage of participants achieving A1C < 7%

    measurement of percentage of participants with A1c less than 7%

    Time frame: From baseline to study completion, up to 12 months

  13. Percentage of participants with time in range > 70%

    measurement of percentage of participants with time in range \> 70%

    Time frame: From baseline to study completion, up to12 months

  14. Percentage of participants with time below range (<70mg/dL) of < 4%

    measurement of percentage of participants with time below range (\<70mg/dL) of \< 4%

    Time frame: From baseline to study completion, up to 12 months

  15. Insulin Usage

    Measure of insulin requirements

    Time frame: From baseline to study completion, up to 12 months

  16. Body Mass Index (BMI) or BMI z-score

    Changes in body mass index

    Time frame: at 6 months and at the end of registry participation, up to 12 months.

  17. EQ-5D (inclusive of the Visual Analogue Scale (VAS))

    Questionaire

    Time frame: at baseline, at 6 months and at the end of registry participation, up to 12 months.

  18. Insulin Delivery Systems: Perceptions, Ideas, Reflections, and Expectations (INSPIRE)

    Questionaire

    Time frame: at baseline, at 6 months and at the end of registry participation, up to 12 months

  19. System Usability Scale (SUS)

    Questionnaire

    Time frame: at baseline, at 6 months and at the end of registry participation, up to 12 months

  20. Incidence rate of prolonged hyperglycemia (events per person months) during usage of Activity Feature

    Measuring rate of prolonged high sugar while in activity feature

    Time frame: From baseline to study completion, up to 12 months

  21. Incidence rate of prolonged hyperglycemia (events per person months)

    Measuring the occurrence of prolonged hyperglycemia

    Time frame: From baseline to study completion, up to 12 months

  22. Incidence rate of prolonged hyperglycemia (events per person months) during usage of a Target Glucose of 140 mg/dL or 150 mg/dL

    Measuring the occurrence of prolonged hyperglycemia while at a set target glucose of 140mg/dL or 150mg/dL

    Time frame: From baseline to study completion, up to 12 months

  23. Glucose Outcomes during the 4-hour post-bolus period using the SmartBolus Calculator: o Percentage of time < 54 mg/dL o Percentage of time in range 70-180 mg/dL

    Glucose metric from study CGM

    Time frame: From baseline to study completion, up to 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Jun 2027, 45 months after the start.

Of 50 industry-sponsored observational studies under Diabetes Mellitus, Type 1, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 45 months is above that.

Counting every sponsor, half of 299 studies reached it within 30 months; a quarter within 12 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2023
First posted
Nov 22, 2023
StartActual
Sep 25, 2023
Primary completionEst.
Jun 2027
CompletionEst.
Sep 2028
Last update
Jul 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06144554
Responsible party
Sponsor
First posted
Nov 22, 2023
Start date
Sep 25, 2023
Primary completion
Jun 2027 (estimated)
Completion
Sep 2028 (estimated)
Last update
Jul 1, 2026

Study contacts

Trang Ly, MBBS, PhD
Contact
APClinical@insulet.com
978-600-7000
Julie Perkins
Contact
jperkins@insulet.com
978-600-7000

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion